Access for the terminally ill to experimental medical innovations: a three-pronged threat

Am J Bioeth. 2007 Oct;7(10):3-6. doi: 10.1080/15265160701672255.
No abstract available

MeSH terms

  • Bias
  • Clinical Trials, Phase I as Topic
  • Drug Evaluation* / economics
  • Drug Evaluation* / ethics
  • Drug Evaluation* / legislation & jurisprudence
  • Drug Industry / economics
  • Drug Industry / ethics
  • Drug Industry / legislation & jurisprudence
  • Drugs, Investigational* / standards
  • Drugs, Investigational* / therapeutic use
  • Ethical Theory
  • Evidence-Based Medicine
  • Female
  • Health Services Accessibility* / ethics
  • Health Services Accessibility* / legislation & jurisprudence
  • Humans
  • Liability, Legal
  • Lobbying
  • Marketing of Health Services* / economics
  • Marketing of Health Services* / ethics
  • Marketing of Health Services* / legislation & jurisprudence
  • Mass Media
  • Patient Rights*
  • Social Responsibility*
  • Terminally Ill* / psychology
  • Therapies, Investigational / standards
  • Treatment Outcome*
  • United States
  • United States Food and Drug Administration
  • Unnecessary Procedures

Substances

  • Drugs, Investigational